Addex has announced plans to move an mGluR2 antagonist into Phase I trials for Alzheimer's disease (AD) in around a year. "We are currently in late-stage optimisation, and plan to have a clinical candidate by the end of the year," Addex's.....

BTG is to regain ahead of schedule the full US marketing rights to the antivenom CroFab (crotalidae polyvalent immune fab (ovine)) and the overdose product DigiFab (digoxin immune fab (ovine)) from Nycomed.

Under the two companies' existing.....

A federal appeals court has affirmed a lower court ruling that Lilly's method-of-use patents for its osteoporosis drug Evista (raloxifene) are valid until 2014, blocking an attempt by Teva Pharmaceutical Industries to sell a generic version before.....

Addex has announced plans to move an mGluR2 antagonist into Phase I trials for Alzheimer's disease (AD) in around a year. "We are currently in late-stage optimisation, and plan to have a clinical candidate by the end of the year," Addex's CEO Dr.....

TiGenix, the Belgium based biotech that spunout its drug discovery activities last week, is focused on becoming a development and marketing company, its CEO Gil Beyen told Scrip.

The company spun out its drug discovery.....

Bionor Pharma of Norway has appointed the former head of clinical development at AstraZeneca, Dr Henrik Lund, as its new CEO.

He took over the position from Trond Syvertsen, a co-founder of the company.

Dr Lund left AstraZeneca a.....

New Zealand expects to save NZ$24 million ($17.1 million) over the next five years following price reductions for certain antipsychotic drugs, said Pharmac, the country's pharmaceutical management agency. It will use the savings to finance other.....

Roche's Japanese subsidiary, Chugai, has made an approval filing for Xeloda (capecitabine) for the treatment of advanced or refractory gastric cancer in patients who are not candidates for curative surgery.

The submission follows a formal.....

The Japanese government is to provide a multi-million dollar subsidy to the country's largest pharma company for the development of cell cultured vaccines for pandemic influenza.

Following an application for the support, Takeda has been.....